BR112018073920A2 - inibidores de pd-1/pd-l1 para tratamento de câncer". - Google Patents
inibidores de pd-1/pd-l1 para tratamento de câncer".Info
- Publication number
- BR112018073920A2 BR112018073920A2 BR112018073920-0A BR112018073920A BR112018073920A2 BR 112018073920 A2 BR112018073920 A2 BR 112018073920A2 BR 112018073920 A BR112018073920 A BR 112018073920A BR 112018073920 A2 BR112018073920 A2 BR 112018073920A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- cancer treatment
- individual
- ligand
- receptor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 title 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 title 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341921P | 2016-05-26 | 2016-05-26 | |
| US62/341,921 | 2016-05-26 | ||
| US201662423358P | 2016-11-17 | 2016-11-17 | |
| US62/423,358 | 2016-11-17 | ||
| US201762471459P | 2017-03-15 | 2017-03-15 | |
| US62/471,459 | 2017-03-15 | ||
| PCT/EP2017/062213 WO2017202744A1 (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018073920A2 true BR112018073920A2 (pt) | 2019-02-26 |
Family
ID=58745241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018073920-0A BR112018073920A2 (pt) | 2016-05-26 | 2017-05-22 | inibidores de pd-1/pd-l1 para tratamento de câncer". |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190144545A1 (enExample) |
| EP (1) | EP3464356A1 (enExample) |
| JP (1) | JP2019516748A (enExample) |
| KR (1) | KR20190012201A (enExample) |
| CN (1) | CN109195989A (enExample) |
| AU (1) | AU2017269675A1 (enExample) |
| BR (1) | BR112018073920A2 (enExample) |
| CA (1) | CA3025391A1 (enExample) |
| IL (1) | IL263178A (enExample) |
| MX (1) | MX2018014435A (enExample) |
| RU (1) | RU2018145184A (enExample) |
| SG (1) | SG11201810423XA (enExample) |
| TW (1) | TW201800108A (enExample) |
| WO (1) | WO2017202744A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| EP3522923A1 (en) * | 2016-10-06 | 2019-08-14 | Pfizer Inc | Dosing regimen of avelumab for the treatment of cancer |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| BR112021008582A8 (pt) * | 2018-11-05 | 2023-02-07 | Merck Sharp & Dohme | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer |
| US20210355223A1 (en) * | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| BR112022001045A2 (pt) * | 2019-07-22 | 2022-07-19 | Seagen Inc | Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20230041654A (ko) | 2020-05-05 | 2023-03-24 | 테온 테라퓨틱스, 인크. | 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도 |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20230128690A (ko) * | 2022-02-28 | 2023-09-05 | 주식회사 시선테라퓨틱스 | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 |
| WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| EP2785375B1 (en) * | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| RU2701327C2 (ru) * | 2013-09-11 | 2019-09-25 | Медиммьюн Лимитед | Антитела к b7-h1 для лечения опухолей |
| AR101210A1 (es) * | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
| CN112263677A (zh) * | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
-
2017
- 2017-05-22 WO PCT/EP2017/062213 patent/WO2017202744A1/en not_active Ceased
- 2017-05-22 KR KR1020187037522A patent/KR20190012201A/ko not_active Withdrawn
- 2017-05-22 MX MX2018014435A patent/MX2018014435A/es unknown
- 2017-05-22 RU RU2018145184A patent/RU2018145184A/ru not_active Application Discontinuation
- 2017-05-22 CA CA3025391A patent/CA3025391A1/en not_active Abandoned
- 2017-05-22 CN CN201780032522.1A patent/CN109195989A/zh active Pending
- 2017-05-22 EP EP17724821.8A patent/EP3464356A1/en not_active Withdrawn
- 2017-05-22 AU AU2017269675A patent/AU2017269675A1/en not_active Abandoned
- 2017-05-22 US US16/304,338 patent/US20190144545A1/en not_active Abandoned
- 2017-05-22 JP JP2018561278A patent/JP2019516748A/ja active Pending
- 2017-05-22 SG SG11201810423XA patent/SG11201810423XA/en unknown
- 2017-05-22 BR BR112018073920-0A patent/BR112018073920A2/pt not_active Application Discontinuation
- 2017-05-25 TW TW106117304A patent/TW201800108A/zh unknown
-
2018
- 2018-11-21 IL IL263178A patent/IL263178A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516748A (ja) | 2019-06-20 |
| KR20190012201A (ko) | 2019-02-08 |
| US20190144545A1 (en) | 2019-05-16 |
| AU2017269675A1 (en) | 2019-01-17 |
| CA3025391A1 (en) | 2017-11-30 |
| SG11201810423XA (en) | 2018-12-28 |
| CN109195989A (zh) | 2019-01-11 |
| TW201800108A (zh) | 2018-01-01 |
| MX2018014435A (es) | 2019-04-15 |
| IL263178A (en) | 2018-12-31 |
| RU2018145184A (ru) | 2020-06-26 |
| WO2017202744A1 (en) | 2017-11-30 |
| EP3464356A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| BR112017018234A2 (pt) | inibidores de pd-1 / pd-l1 para o tratamento de câncer | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| BR112017018758A2 (pt) | alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide | |
| BR112018071023A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose | |
| MX2021004709A (es) | Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| BR112019025478A8 (pt) | Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer | |
| MX2020001759A (es) | Inhibidores de histona acetiltransferasa de la familia myst. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |